The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The global gastroparesis market is projected to increase from $6.08 billion in 2022 to $6.44 billion in 2023, with a 5.9% CAGR, and is anticipated to reach $7.77 billion in 2027 at a 4.8% CAGR.

North America held the largest gastroparesis market share.

Gastroparesis Market Driver
The rising occurrence of gastroparesis fuels the gastroparesis market. Gastroparesis, a condition hindering stomach-to-intestine food transit, results from hypothyroidism, autoimmune disorders, vagus nerve injury, and viral stomach infections. Medication for gastroparesis enhances stomach muscle contractions and emptying. For instance, a 2021 research study from Practice Update reported an overall gastroparesis prevalence of 267.7 per 100,000 individuals in the US, with a definite gastroparesis prevalence of 21.5 per 100,000. Consequently, the increasing gastroparesis prevalence propels the market.

View More On The Gastroparesis Market Report 2023 – https://www.thebusinessresearchcompany.com/report/gastroparesis-global-market-report

Prominent Gastroparesis Market Trend
Innovative drug development for gastroparesis treatment is a leading trend, with major companies creating advanced formulations like Evoke Pharma’s metoclopramide nasal spray, the first nasally administered medication for diabetic gastroparesis approved by the US FDA.

Gastroparesis Market Prominent Players
Major players in the gastroparesis market are Pfizer Inc., GlaxoSmithKline plc., Abbott Laboratories Inc., AstraZeneca Plc., Medtronic Plc., Takeda Pharmaceutical Company Limited, Novo Nordisk AS, Johnson And Johnson Services Inc., Teva Pharmaceutical Industries Ltd, AbbVie Inc., Boston Scientific Corporation, Bausch Health Companies Inc., Cadila Pharmaceuticals Ltd., Daewoong Pharmaceutical co. ltd, ReGenXBio Inc., ANI Pharmaceuticals Inc., Dompe Farmaceutici S.p.A, Sucampo Pharmaceuticals Inc., Ironwood Pharmaceuticals Inc., Orexo AB, Theravance Biopharma Inc., RQI Partners LLC., RedHill Biopharma Ltd., Synthorx Inc., Valeant Pharmaceuticals International Inc., CinRx Pharma LLC., Ritter Pharmaceuticals Inc., Evoke Pharma Inc., Metacrine Inc., and Neurogastrx Inc.

Request A Sample Of The Global Gastroparesis Market Report 2023:
https://www.thebusinessresearchcompany.com/sample_request?id=12189&type=smp

Key Gastroparesis Market Segments
The global gastroparesis market is segmented –
1) By Treatment Modality: Medications, Dietary Modifications, Medical Devices, Other Therapies
2) By Gastroparesis Type: Idiopathic, Diabetic, Post- Surgical, Other Types
3) By Patient Demographics: Pediatric Gastroparesis, Adult Gastroparesis
4) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Other Distribution Channels
5) By End User: Hospitals And Clinics, Ambulatory Surgical Centers, Home Care Settings

The Gastroparesis Global Market Report 2023  provides a comprehensive overview on the gastroparesis market size, trends and drivers, opportunities, strategies, and companies analysis. The countries covered in the gastroparesis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

View More Related Reports –
Neurostimulation Devices Global Market Report 2023
Internal Neuromodulation Devices Global Market Report 2023
Gastrointestinal Devices Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model